Jpmorgan Chase & CO Soma Logic, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$1.76 - $2.83 $341,202 - $548,637	193,865 New	193,865 $490,000
Q4 2023 Feb 12, 2024	BUY	$1.76 - $2.83 $4,127 - $6,636	2,345 Added 1.22%	193,865 $490,000
Q3 2023 Nov 14, 2023	SELL	$1.99 - $2.45 $45,680 - $56,239	-22,955 Reduced 10.7%	191,520 $457,000
Q2 2023 Aug 11, 2023	SELL	$2.1 - $3.36 $40,494 - $64,790	-19,283 Reduced 8.25%	214,475 $495,000
Q1 2023 May 18, 2023	BUY	$2.13 - $3.6 $411,716 - $695,858	193,294 Added 477.69%	233,758 $596,000
Q1 2023 May 11, 2023	SELL	$2.13 - $3.6 $242,204 - $409,359	-113,711 Reduced 73.75%	40,464 $103,000
Q4 2022 Feb 13, 2023	BUY	$2.05 - $3.47 $32,455 - $54,937	15,832 Added 11.44%	154,175 $387,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $5.47 $2,519 - $21,874	3,999 Added 2.98%	138,343 $401,000
Q2 2022 Aug 11, 2022	BUY	$4.27 - $8.26 $573,648 - $1.11 Million	134,344 New	134,344 $608,000
Q4 2021 Feb 10, 2022	SELL	$10.49 - $14.28 $255,053 - $347,203	-24,314 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$9.94 - $12.77 $241,681 - $310,489	24,314 New	24,314 $301,000

7.48M

Ticker SLGC
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 183,452,992
Description
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex prot...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.